#1 Clinical Trials Search in Europe

Mk-0616

This article discusses a clinical trial investigating the drug MK-0616, which is being studied for the treatment of hypercholesterolemia (high cholesterol). The trial aims to compare the bioavailability of different formulations of MK-0616, including capsules and tablets, in healthy adult participants. By examining how the body processes these various forms, researchers hope to determine the most effective way to administer the medication for future treatments.

Table of Contents

What is MK-0616?

MK-0616 is a new drug that is currently being studied for its potential to treat high cholesterol levels in the blood. It is still in the research phase, which means it’s not yet available for general use and doctors are still learning about how it works and its effects on the body.[1]

What Condition Does MK-0616 Treat?

The main condition that MK-0616 is being developed to treat is called hypercholesterolemia. This is a medical term for high cholesterol levels in the blood. High cholesterol can be dangerous because it can lead to heart disease and other serious health problems.[1]

How is MK-0616 Administered?

According to the research information, MK-0616 is taken orally. This means it’s a medicine that you swallow, likely in the form of a capsule or tablet. The study is looking at different forms of the drug to see which one works best.[1]

Current Research on MK-0616

A clinical trial is currently underway to study MK-0616. This trial is designed to understand how the drug behaves in the body when given in different forms. The researchers believe that changing the form of MK-0616 (for example, from a capsule to a tablet) doesn’t affect how it works in a healthy person’s body.[1]

The study is what’s called a “crossover” study. This means that each participant in the study will try different forms of the drug at different times, with breaks in between. This helps researchers compare how each form of the drug works in the same person.[1]

What Researchers Are Studying

The researchers are looking at several important aspects of how MK-0616 works in the body:[1]

  • How much of the drug gets into the bloodstream: This is measured in different ways, including how much of the drug is in the blood over time (AUC) and the highest level of the drug in the blood (Cmax).
  • How long the drug stays in the body: This is measured by looking at how long it takes for half of the drug to leave the body (half-life).
  • How quickly the drug starts working: This is measured by looking at how long it takes for the drug to reach its highest level in the blood (Tmax).

Safety Considerations

As with any new drug, researchers are carefully monitoring the safety of MK-0616. They are tracking any side effects (called adverse events) that participants might experience. This includes both minor side effects and any serious effects that might cause someone to stop taking part in the study.[1]

It’s important to note that this drug is still in the testing phase. More research is needed to fully understand its effectiveness and safety before it can be considered for approval and use in treating patients with high cholesterol.

Aspect Details
Study Drug MK-0616
Condition Studied Hypercholesterolemia
Study Design Open-label, randomized, single-dose, 3-period, crossover study
Participants Healthy adult volunteers
Formulations Tested Reference capsule, Formulation 1 (F1), Formulation 2 (F2)
Primary Outcomes AUC0-Inf, AUC0-24hr, AUC0-Last, Cmax, C24, t1/2, Tmax of MK-0616
Secondary Outcomes Number of participants experiencing adverse events, Number of participants discontinuing due to adverse events
Study Duration Approximately 2 months

FAQ

  • What is the purpose of this clinical trial? The main goal of this trial is to study how different forms of MK-0616 (capsules and tablets) affect the levels of the drug in the blood. Researchers want to compare the bioavailability of these different formulations in healthy adults.
  • Who can participate in this trial? This trial is designed for healthy adult participants. The study focuses on people without the condition being treated (hypercholesterolemia) to understand how the drug behaves in a healthy body.
  • How is the trial structured? The trial is divided into three periods, each lasting 15 days. Participants are randomly assigned to one of six sequences, receiving different formulations of MK-0616 in each period. There is a 14-day washout period between each treatment period.
  • What measurements are being taken during the trial? Researchers are measuring various aspects of how the drug behaves in the body, including how much of the drug is in the blood over time (AUC), the highest concentration of the drug in the blood (Cmax), how long it takes for the drug to reach its highest concentration (Tmax), and how long it takes for the drug to leave the body (half-life).
  • Are there any safety measures in place? Yes, the trial monitors for adverse events (AEs), which are any unexpected medical occurrences during the study. The number of participants experiencing AEs and those who discontinue the study due to AEs will be reported, ensuring participant safety is closely monitored.

Ongoing Clinical Trials on Mk-0616

  • Study on MK-0616 for Reducing Heart Disease Events in Patients with Atherosclerotic Cardiovascular Disease

    Not yet recruiting

    3 1
    Investigated drugs:
    Denmark

  • Study on the Effects and Safety of MK-0616 for Adults with High Cholesterol

    Not yet recruiting

    3 1
    Investigated drugs:
    Germany Italy Spain

Glossary

  • Hypercholesterolemia: A condition characterized by high levels of cholesterol in the blood, which can increase the risk of heart disease and stroke.
  • Bioavailability: The extent and rate at which a drug enters the body's circulation and becomes available at the site of action.
  • Formulation: The way a drug is prepared and presented, such as in capsule or tablet form.
  • Washout period: A period of time between treatments in a clinical trial when participants do not receive any medication, allowing the effects of the previous treatment to wear off.
  • AUC (Area Under the Curve): A measure of the total exposure to a drug over time, calculated from blood concentration data.
  • Cmax: The maximum concentration of a drug observed in the blood after administration.
  • Tmax: The time it takes for a drug to reach its maximum concentration in the blood.
  • Half-life: The time it takes for the concentration of a drug in the body to decrease by half.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.

References

  1. https://clinicaltrials.gov/study/NCT06592339